Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year ...
Barchart Research What to Expect from ONC Earnings ONC Generated May 5, 2026 Current Price $297.49 EPS Estimate $$0.73 Consensus Rating Strong Buy Average Move 4.66% BeOne Medicines Delivers Quarterly...
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging disease Results...
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open....
Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periods Global...
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: ...
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial...
Company outlines foundational hematology leadership, multiple 2026 data catalysts, a unique global clinical development superhighway, and continued financial excellence
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status High GEA burden in Asia, where BeOne holds...
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13,...